NCT05524961Completed
Bright Light Therapy for Non-motor Symptoms in Parkinson's Disease
Randomized Placebo- and Active-controlled Trial for Assessing the Efficacy of Bright Light Therapy for Sleep and Mood Symptoms in Patients With Parkinson's Disease
Source: ClinicalTrials.gov · Last updated 20 Mar 2026
Brief summary (registry, in English)
This is a randomized placebo- and active-controlled trial for assessing the efficacy of bright light therapy for sleep and mood symptoms in patients with Parkinson's disease
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 69 (actual)
- First submitted
- 25 Aug 2022
- Start date
- 9 Dec 2022
- Primary completion date
- 3 Oct 2025
- Lead sponsor
- Chinese University of Hong Kong
- Diseases
- Parkinson disease
- NCT number
- NCT05524961
What you commit to
- Study type: Interventional
- Participants enrolled: 69
- From 9 Dec 2022 to the primary completion date, 3 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with deep brain stimulation (DBS) implant
Other illness
- A current or past history of manic or hypomanic episode, schizophrenia, mental retardation, or substance use disorder. (Subjects with depression or anxiety disorders will not be excluded)
- Unstable medical or psychiatric condition
- Cognitive impairment with score of 19 or below by the Hong Kong version of Montreal Cognitive Assessment (HK-MoCA)
- Contraindication to bright light therapy: history of light induced migraine. Epilepsy, current use of photosensitizing medications, presence of eye disease, e.g. retinal disease, severe cataract, glaucoma and blindness
- Significant medical condition/ hearing impairment/ speech deficit lead to incapability in completing clinical interview
- Patients with known sleep disorders, eg. untreated severe sleep apnea, restless leg syndrome
Other
- Presence of substantial suicidal risk as judged by the clinician and/or screening instruments
- Presence of active psychotic symptoms that might impair the ability to consent or validity of the interview
- Regular shift worker or trans-meridian flight in the past three months
- Enrolment in another clinical trial of an investigational medicinal product or device
- Subjects who are on exogenous melatonin
Who the study is looking for
- Idiopathic Parkinson's disease diagnosed by neurologist according to the UK Parkinson's Disease Society Brain Bank clinical diagnostic criteria
- Capable to give informed consent
- Maintained on stable dose of medications for Parkinson's disease/psychotropic drugs for at least four weeks prior to entry of the study
- Score 14 or more on the Epworth Sleepiness Scale
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The Chinese University of Hong Kong Coordinator of this site? Confirm its status | Hong Kong | Hong Kong | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.